These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 34472087)

  • 1. Identifiability of Biologicals: An Analysis Using EudraVigilance, the European Union's Database of Reports of Suspected Adverse Drug Reactions.
    Correia Pinheiro L; Giezen TJ; Wolff-Holz E; Weise M; Laslop A; Hidalgo-Simon A
    Clin Pharmacol Ther; 2021 Nov; 110(5):1311-1317. PubMed ID: 34472087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identifiability of Biologicals in Adverse Drug Reaction Reports Received From European Clinical Practice.
    Vermeer NS; Giezen TJ; Zastavnik S; Wolff-Holz E; Hidalgo-Simon A
    Clin Pharmacol Ther; 2019 Apr; 105(4):962-969. PubMed ID: 30460997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EU pharmacovigilance regulatory requirements of anticancer biosimilar monoclonal antibodies.
    Francescon S; Fornasier G; Baldo P
    Int J Clin Pharm; 2018 Aug; 40(4):778-782. PubMed ID: 30094558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety profile of biological medicines as compared with non-biologicals: an analysis of the italian spontaneous reporting system database.
    Cutroneo PM; Isgrò V; Russo A; Ientile V; Sottosanti L; Pimpinella G; Conforti A; Moretti U; Caputi AP; Trifirò G
    Drug Saf; 2014 Nov; 37(11):961-70. PubMed ID: 25255847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current state of biologic pharmacovigilance in the European Union: improvements are needed.
    Felix T; Jordan JB; Akers C; Patel B; Drago D
    Expert Opin Drug Saf; 2019 Mar; 18(3):231-240. PubMed ID: 30714424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is pharmacovigilance of biologicals cost-effective?
    Claus B
    Int J Clin Pharm; 2018 Aug; 40(4):787-789. PubMed ID: 30051230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Traceability of biopharmaceuticals in spontaneous reporting systems: a cross-sectional study in the FDA Adverse Event Reporting System (FAERS) and EudraVigilance databases.
    Vermeer NS; Straus SM; Mantel-Teeuwisse AK; Domergue F; Egberts TC; Leufkens HG; De Bruin ML
    Drug Saf; 2013 Aug; 36(8):617-25. PubMed ID: 23771794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EU's new pharmacovigilance legislation: considerations for biosimilars.
    Calvo B; Zuñiga L
    Drug Saf; 2014 Jan; 37(1):9-18. PubMed ID: 24190573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The UK BIO-TRAC Study: A Cross-Sectional Study of Product and Batch Traceability for Biologics in Clinical Practice and Electronic Adverse Drug Reaction Reporting in the UK.
    Klein K; Hazell L; Stolk P; Shakir S
    Drug Saf; 2020 Mar; 43(3):255-263. PubMed ID: 31872358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mapping the safety profile of biologicals: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase.
    Giezen TJ; Mantel-Teeuwisse AK; Meyboom RH; Straus SM; Leufkens HG; Egberts TC
    Drug Saf; 2010 Oct; 33(10):865-78. PubMed ID: 20812771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological agents and biosimilars: Essential information for the internist.
    Pasina L; Casadei G; Nobili A
    Eur J Intern Med; 2016 Sep; 33():28-35. PubMed ID: 27342030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Impact of Mandatory Reporting of Non-Serious Safety Reports to EudraVigilance on the Detection of Adverse Reactions.
    Candore G; Monzon S; Slattery J; Piccolo L; Postigo R; Xurz X; Strauss S; Arlett P
    Drug Saf; 2022 Jan; 45(1):83-95. PubMed ID: 34881404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of exposure misclassification in spontaneous ADR reports on the time to detection of product-specific risks for biologicals: a simulation study.
    Vermeer NS; Ebbers HC; Straus SM; Leufkens HG; Egberts TC; De Bruin ML
    Pharmacoepidemiol Drug Saf; 2016 Mar; 25(3):297-306. PubMed ID: 26676881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reducing the noise in signal detection of adverse drug reactions by standardizing the background: a pilot study on analyses of proportional reporting ratios-by-therapeutic area.
    Grundmark B; Holmberg L; Garmo H; Zethelius B
    Eur J Clin Pharmacol; 2014 May; 70(5):627-35. PubMed ID: 24599513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biopharmaceuticals safety perception in Slovakia: considerations and real-life pharmacovigilance data.
    Lassanova M; Liskova S; Tisonova J; Fundarkova S; Lassan S
    Bratisl Lek Listy; 2021; 122(7):443-448. PubMed ID: 34161110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions.
    Bennett CL; Schoen MW; Hoque S; Witherspoon BJ; Aboulafia DM; Hwang CS; Ray P; Yarnold PR; Chen BK; Schooley B; Taylor MA; Wyatt MD; Hrushesky WJ; Yang YT
    Lancet Oncol; 2020 Dec; 21(12):e575-e588. PubMed ID: 33271114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EudraVigilance Medicines Safety Database: Publicly Accessible Data for Research and Public Health Protection.
    Postigo R; Brosch S; Slattery J; van Haren A; Dogné JM; Kurz X; Candore G; Domergue F; Arlett P
    Drug Saf; 2018 Jul; 41(7):665-675. PubMed ID: 29520645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Geographical variation in reporting Interstitial Lung Disease as an adverse drug reaction: findings from an European Medicines Agency analysis of reports in EudraVigilance.
    Pinheiro L; Blake K; Januskiene J; Yue QY; Arlett P
    Pharmacoepidemiol Drug Saf; 2016 Jun; 25(6):705-12. PubMed ID: 27004571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real World Data on the Utilization Pattern and Safety Profile of Infliximab Originator Versus Biosimilars in Italy: A Multiregional Study.
    Scavone C; Sessa M; Clementi E; Corrao G; Leone R; Mugelli A; Rossi F; Spina E; Capuano A
    BioDrugs; 2018 Dec; 32(6):607-617. PubMed ID: 30341487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacovigilance of Biologics in a Multisource Environment.
    Sagi S; Cohen HP; Woollett GR
    J Manag Care Spec Pharm; 2017 Dec; 23(12):1249-1254. PubMed ID: 29172979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.